[go: up one dir, main page]

WO1994008578A3 - Activite tumoricide des ansamycines benzoquinonoides contre le cancer de la prostate et les malignites neurales primitives - Google Patents

Activite tumoricide des ansamycines benzoquinonoides contre le cancer de la prostate et les malignites neurales primitives Download PDF

Info

Publication number
WO1994008578A3
WO1994008578A3 PCT/US1993/009858 US9309858W WO9408578A3 WO 1994008578 A3 WO1994008578 A3 WO 1994008578A3 US 9309858 W US9309858 W US 9309858W WO 9408578 A3 WO9408578 A3 WO 9408578A3
Authority
WO
WIPO (PCT)
Prior art keywords
malignancies
prostate cancer
against prostate
tumoricidal activity
primitive neural
Prior art date
Application number
PCT/US1993/009858
Other languages
English (en)
Other versions
WO1994008578A2 (fr
Inventor
Luke Whitesell
Leonard Neckers
Jane Trepel
Charles Myers
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Priority to AU53606/94A priority Critical patent/AU5360694A/en
Priority to EP93923891A priority patent/EP0664702A1/fr
Priority to JP6510285A priority patent/JPH08502488A/ja
Priority to CA002146668A priority patent/CA2146668A1/fr
Publication of WO1994008578A2 publication Critical patent/WO1994008578A2/fr
Publication of WO1994008578A3 publication Critical patent/WO1994008578A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Procédés et compositions pour le traitement de certains malignités chez l'homme, comprenant l'utilisation de certains ansamycine-benzoquinones.
PCT/US1993/009858 1992-10-14 1993-10-14 Activite tumoricide des ansamycines benzoquinonoides contre le cancer de la prostate et les malignites neurales primitives WO1994008578A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU53606/94A AU5360694A (en) 1992-10-14 1993-10-14 Tumoricidal activity of benzoquinonoid ansamycins against prostate cancer and primitive neural malignancies
EP93923891A EP0664702A1 (fr) 1992-10-14 1993-10-14 Activite tumoricide des ansamycines benzoquinonoides contre le cancer de la prostate et les malignites neurales primitives
JP6510285A JPH08502488A (ja) 1992-10-14 1993-10-14 前立腺癌および初期神経悪性疾患に対するベンゾキノイドアンサマイシンの殺腫瘍活性
CA002146668A CA2146668A1 (fr) 1992-10-14 1993-10-14 Activite tumoricide d'ansamycines benzoquinonoides contre le cancer de la prostate et les tumeurs malignes primitives du systeme nerveux

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96125092A 1992-10-14 1992-10-14
US07/961,250 1992-10-14

Publications (2)

Publication Number Publication Date
WO1994008578A2 WO1994008578A2 (fr) 1994-04-28
WO1994008578A3 true WO1994008578A3 (fr) 1994-06-23

Family

ID=25504242

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/009858 WO1994008578A2 (fr) 1992-10-14 1993-10-14 Activite tumoricide des ansamycines benzoquinonoides contre le cancer de la prostate et les malignites neurales primitives

Country Status (5)

Country Link
EP (1) EP0664702A1 (fr)
JP (1) JPH08502488A (fr)
AU (1) AU5360694A (fr)
CA (1) CA2146668A1 (fr)
WO (1) WO1994008578A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1413885A3 (fr) * 1997-04-02 2004-08-11 Takeda Chemical Industries, Ltd. Utilisation et méthode de criblage d'un activeur d'un produit génétique aberrant
WO1999051223A1 (fr) * 1998-04-03 1999-10-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Ansamycines benzoquinoides pour le traitement d'une crise ou d'un arret cardiaque
AU2986800A (en) * 1999-02-08 2000-08-25 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of inhibiting the hgf-met-upa-plasmin network
US6174875B1 (en) 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
AU4678300A (en) 1999-04-30 2000-11-17 Slil Biomedical Corporation Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
WO2002038105A2 (fr) 2000-11-08 2002-05-16 Slil Biomedical Corporation Nouveaux conjugues d'acide amine et d'analogues de polyamine utiles en tant qu'agents anticancer
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
US6649587B1 (en) 1999-04-30 2003-11-18 Slil Biomedical Corporation Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
WO2005009345A2 (fr) 2003-06-13 2005-02-03 Kosan Biosciences, Inc. Composes de 2-desmethyl ansamycine
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
WO2005056531A1 (fr) 2003-11-12 2005-06-23 Kosan Biosciences, Inc. Composes 11-o-methylgeldanamycine
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
JP2007530596A (ja) * 2004-03-26 2007-11-01 バン アンデル リサーチ インスティチュート ゲルダナマイシンおよび誘導体はガン浸潤を阻害し、新規な標的を同定する
US7259156B2 (en) 2004-05-20 2007-08-21 Kosan Biosciences Incorporated Geldanamycin compounds and method of use
US7608611B2 (en) * 2005-03-11 2009-10-27 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor
CN101213178A (zh) * 2005-06-29 2008-07-02 协和发酵工业株式会社 苯环型安莎霉素衍生物
GB0606542D0 (en) * 2006-03-31 2006-05-10 Biotica Tech Ltd Novel compounds and methods for their production
GB0606554D0 (en) * 2006-03-31 2006-05-10 Biotica Tech Ltd Novel compounds and methods for their production
GB0609117D0 (en) * 2006-05-09 2006-06-21 Biotica Tech Ltd Novel compounds
CA2669820A1 (fr) 2006-11-15 2008-05-22 Abraxis Bioscience, Llc Derives d'analogues de l'hydroquinone de geldamycine substitues par 18-amino presentant une activite cytotoxique pour le traitement du cancer
EP2190291B1 (fr) 2007-08-23 2015-10-14 The Regents of The University of Colorado, A Body Corporate Inhibiteurs de hsp90 avec toxicité modifiée
WO2009036092A2 (fr) 2007-09-10 2009-03-19 University Of Massachusetts Agents antitumoraux ciblant les mitochondries
US9603829B2 (en) 2011-11-14 2017-03-28 The Regents Of The University Of Colorado, A Body Corporate HSP90 inhibitors with modified toxicity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2042523A (en) * 1979-02-19 1980-09-24 Kaken Chemical Co Geldanamycin derivatives and anti-tumor drug
DE3234203A1 (de) * 1981-09-17 1983-07-07 Takeda Chemical Industries, Ltd., Osaka Macbecin-derivate und deren herstellung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2042523A (en) * 1979-02-19 1980-09-24 Kaken Chemical Co Geldanamycin derivatives and anti-tumor drug
DE3234203A1 (de) * 1981-09-17 1983-07-07 Takeda Chemical Industries, Ltd., Osaka Macbecin-derivate und deren herstellung

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
L.WHITESELL ET AL.: "Benzoquinonoid Ansamycins Possess Selective Tumoricidal Activity Unrelated to src Kinase Inhibition", CANCER RES., vol. 52, no. 7, 1 April 1992 (1992-04-01), pages 1721 - 1728 *
M. MATSUMOTO: "Inhibitors for Protein Tyrosine Kinases, Erbstatin, Genistein and Hernimycin A, Induce Differentiation of Human Neural Tumor Cell Lines", NIPPON GEKA HOKAN (ARCH. JPN. CHIR.), vol. 60, no. 2, 1 March 1991 (1991-03-01), pages 113 - 121 *
P.N.PREIS ET AL.: "Neuronal Cell Differentiation of Human Neuroblastoma Cells by Retinoic Acid plus Herbimycin A", CANCER RES., vol. 48, no. 22, 15 November 1988 (1988-11-15), pages 6530 - 6534 *

Also Published As

Publication number Publication date
WO1994008578A2 (fr) 1994-04-28
EP0664702A1 (fr) 1995-08-02
JPH08502488A (ja) 1996-03-19
CA2146668A1 (fr) 1994-04-28
AU5360694A (en) 1994-05-09

Similar Documents

Publication Publication Date Title
WO1994008578A3 (fr) Activite tumoricide des ansamycines benzoquinonoides contre le cancer de la prostate et les malignites neurales primitives
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
IL189132A0 (en) Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer
AU6276194A (en) Use of monoterpenes, sesquiterpernes and diterpernes for the treatment of cancer
HUP9902068A3 (en) Methods and compositions for the diagnosis and treatment of cancer
DE59611481D1 (en) Chromatin-regulatorgene
CA2255891A1 (fr) Compositions et methodes pour traiter ou prevenir des maladies des voies corporelles
AP9700939A0 (en) Compounds and methods for the treatment of cancer
AU7012496A (en) Compounds and methods for treatment and diagnosis of prostate cancer
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
AU4473596A (en) Methods of human prostate cancer diagnosis
AU1575697A (en) Compositions and methods for the treatment and diagnosis of cancer
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
WO1998030585A3 (fr) Utilisation de pea3 en tant que suppresseur de tumeurs
IL101410A0 (en) Formulation for the treatment of cancer
AU2476200A (en) Ribozyme therapy for the treatment and/or prevention of restenosis
BG102667A (en) Diosgenine-containing composition
CA2282682A1 (fr) Traitement du psoriasis par le tazarotene et des corticoides
AU7105498A (en) Combination therapy for the prevention and treatment of osteoporosis
AU1278600A (en) Novel therapeutic application of nicergoline
EP0733365A3 (fr) Utilisation des benzoquinolin-3-ones pour le traitement et la prévention du cancer de prostate
AU3274597A (en) Remedies and preventives for stomatitis
HUP9802536A3 (en) Pharmaceutical compositions containing 1,2,4-benzotriazine 1,4-dioxide and use thereof for the preparation of pharmaceutical compositions treating cancer
AU1569700A (en) Novel therapeutic application of low molecular weight heparin
AU4417996A (en) Treatment of prostate cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2146668

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993923891

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993923891

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993923891

Country of ref document: EP